Sector News

Axovant COO McCourt jumped into Regeneron's top commercial post

February 14, 2018
Life sciences

Beleaguered biotech Axovant announced Monday that President and COO Marion McCourt would be departing “to pursue another opportunity” as part of a larger executive shakeup that also claimed CEO David Hung. And as it turns out, McCourt’s opportunity is with Regeneron.

The New York biotech this week publicly named (PDF) McCourt as its new SVP and commercial head. She’ll lead “all aspects” of product commercialization for Regeneron’s already approved drugs, as well as its development-stage pipeline, the company said.

McCourt will be replacing Bob Terifay, who early last month resigned as commercial EVP. He’ll officially retire from the company on July 31 after a medical leave of absence wraps up.

As CEO Len Schleifer pointed out in a statement, McCourt has an opportunity to make a big impact at her new employer, considering that the company boasts 15 late-stage programs that could land new approvals or indications.

“Marion will play a critical role in shaping Regeneron’s future and ensuring our innovative medicines reach patients in need,” he said.

She’ll also be responsible for steering blockbuster and lead drug Eylea through potential competition down the line, as well as keeping it churning out double-digit growth more than six years after its first approval. To do that, she’ll need to help the product push further into diabetic eye diseases, an area management says remains relatively untapped.

Plus, she’ll be tasked with the ongoing launch of three drugs Regeneron shares with Sanofi:
1.Cholesterol-fighter Praluent, which entered the market to great fanfare only to come up against serious payer obstacles.
2.Dupixent, the atopic dermatitis drug that’s already catching on.
3.Kevzara, a rheumatoid arthritis product that’s competing in an already-crowded field.

McCourt has plenty of commercial experience to draw on in her new role, though. After kicking off her career with 12 years at AstraZeneca, she went on to serve as VP of Amgen’s U.S. commercial operations and VP and general manager of its bone health and primary care business units. She also held a C-suite post at Medivation until Pfizer bought it out, at which time she joined then-Medivation CEO Hung in jumping over to Axovant.

In addition to Hung and McCourt, Axovant directors Kate Falberg, Tony Vernon and Patrick Machado also left the company Monday.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

November 26, 2023

ViCentra links insulin pump with Dexcom, Diabeloop tech to launch closed-loop diabetes system in Europe

Life sciences

Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.

November 26, 2023

Boehringer builds out cancer capabilities with $500M deal for bacteria-focused Swiss biotech

Life sciences

Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.

November 26, 2023

EuroAPI completes acquisition of BianoGMP

Life sciences

EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.

How can we help you?

We're easy to reach